ESMO Open

Papers
(The H4-Index of ESMO Open is 48. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Table of Contents297
Table of Contents203
Unfavorable carcinoma of unknown primary with a gastrointestinal profile: a retrospective study174
164P Clinical utility of comprehensive molecular profiling tests for advanced gastrointestinal tumors155
57P Two cases of adult rhabdomyosarcoma of the head and neck successfully treated with pazopanib126
60P The diagnostic pathway of sarcoma patients: Results from the QUEST study in the Netherlands and the United Kingdom: A cohort study118
61P Pazopanib in the real-world setting: Data from the Italian national registry117
22P Exploring exportin-1 as a therapeutic vulnerability in lung squamous cell carcinoma114
70P Total neoadjuvant vs standard perioperative cisplatin/doxorubicin chemotherapy in patients with extremities osteosarcoma: A single-center cohort study112
169P A real-world molecular pre-screening program in advanced breast cancer (ABC) at Institut Català d'Oncologia l'Hospitalet: Clinical practice study to assess treatment-decision choice based on mole103
73P Proton radiotherapy in treatment of desmoid tumors101
104P Choline transporter-like protein 1 is a novel molecular target for the treatment of hepatocellular carcinoma101
OP01-3 A phase II study on the efficacy of regorafenib in treating patients with c-KIT-mutated metastatic malignant melanoma that progressed after previous treatment (KCSG-UN-14-13)91
5P Tisotumab vedotin (TV) dose schedule optimization in non-cervical populations85
32P Expression of STAT3 and hypoxia markers in repeatedly resected glioma patients84
OP02-1 Safety and efficacy of eribulin in patients with advanced or metastatic breast cancer previously treated with anthracycline and taxane in real-world clinical practice: Data from post-marketing 83
91P Management challenges of extremity sarcomas in under-resourced settings: The first survey-based study in Morocco82
22P Emerging role of histone acetyltransferase CBP in breast cancer cells undergoing DNA damage82
100P Combinatorial treatment strategies for overcoming the immunotherapy resistance in soft tissue sarcomas82
30P Deep learning approach for discovering new predictive histological features of immunotherapy response82
104P Multi-omic profiling and real-time ex vivo modelling of imatinib-resistant dermatofibrosarcoma protuberans with fibrosarcomatous transformation82
37P Dose transition pathways for time-to-event continual reassessment method (TITE-CRM): Will imposing a waiting time result in better performance?79
107P The actin cytoskeleton as a new target structure for metastasizing osteosarcoma78
111P A novel immune cell signature for predicting pleomorphic sarcoma prognosis77
PP049 Redistribution of 8-oxo-G/AP sites hot spots mediated transcription alteration is a novel and ubiquitous mechanism in EGFR-TKI resistance of NSCLC75
PP171 Therapeutic influence of simvastatin on MCF-7 and MDA-MB-231 breast cancer cells via mitochondrial depletion and improvement in chemosensitivity of cytotoxic drugs73
European Society for Medical Oncology (ESMO)73
PP106 Identifying apoptosis-inducing genes in human osteosarcoma cell lines and their potential use in immunotherapy73
PP157 Metformin prevents tumor cell growth and invasion of human hormonal breast cancer cells via the diabetes-related gene inhibition71
107P Inhibition of hydrogen sulfide biosynthesis influences mitochondrial biogenesis in breast cancer70
100P Impact of IDH mutation and adjuvant chemo(radio)therapy on survival outcome in grade II/III astrocytoma68
116P Targeting mitochondrial biogenesis in the ‘CYBRID’ model of chronic lymphocytic leukemia for improving cancer related fatigue after chemotherapy67
17P Homologous recombination deficiency status in consecutive tumor biopsies in late-stage cancer patients66
25O Phase I tolerability, persistence and pharmacodynamic (PD) profile of IV-administered next-generation adenoviral vectors supports clinical expansion in solid cancers62
83P Cost-effectiveness analysis of talazoparib maintenance treatment for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US60
34P Cocktail peptide vaccines targeting cancer stem cells for enhanced therapeutic efficacy in oral cancers58
36P Development of patient-derived explant model as a robust preclinical tool to predict the efficacy of ICB-based immunotherapy in colorectal cancer patients55
104P A comprehensive analysis of the molecular landscape of HER3 expression in adenocarcinoma of the lung55
35P Beyond microsatellite testing: Tumor mutational burden, should it be routine in patients with GI cancers?55
24P New hybrid camptothecin-based molecules: Promising antitumor agents for the treatment of hematological malignancies54
24P Sinonasal neuroendocrine tumors: Analysis of therapeutic strategies in an ultra-rare tumor54
Acknowledgements54
18P A translational project of the WSG-ADAPT-TN trial demonstrates immunomodulatory and anti-viral defense gene networks predicting pathological complete response (pCR) and survival after de-escalated52
Title Page51
29P Prevalence of high tumor mutational burden (TMB) in patients with metastatic breast cancer (mBC) assessed by liquid biopsy (LB)51
39P A validation study of a self-testing capillary kit, the rhelise kit for therapeutic dose monitoring (TDM) of tamoxifen, Z-endoxifen, and 4-hydroxytamoxifen in breast cancer patients50
23P Prognostic value of tumor-infiltrating lymphocytes (TILs) and soluble immune checkpoints in early triple-negative breast cancer (TNBC)48
42P Conflicting results of BCL2 based on HER2 status in patients with breast cancer48
0.30331301689148